Europe Parkinson’s Disease Treatment Market Size & Outlook
Related Markets
Europe parkinson’s disease treatment market highlights
- The Europe parkinson’s disease treatment market generated a revenue of USD 1,565.2 million in 2024.
- The market is expected to grow at a CAGR of 5.1% from 2025 to 2030.
- In terms of segment, carbidopa-levodopa was the largest revenue generating drug class in 2024.
- Carbidopa-Levodopa is the most lucrative drug class segment registering the fastest growth during the forecast period.
- Country-wise, UK is expected to register the highest CAGR from 2025 to 2030.
Europe data book summary
| Market revenue in 2024 | USD 1,565.2 million |
| Market revenue in 2030 | USD 2,114.1 million |
| Growth rate | 5.1% (CAGR from 2025 to 2030) |
| Largest segment | Carbidopa-levodopa |
| Fastest growing segment | Carbidopa-Levodopa |
| Historical data covered | 2018 - 2023 |
| Base year for estimation | 2024 |
| Forecast period covered | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Carbidopa-Levodopa, Dopamine Agonist, MAO-B Inhibitors, COMT inhibitors, Anticholinergics |
| Key market players worldwide | Novartis AG ADR, Teva Pharmaceutical Industries Ltd, Merck & Co Inc, GSK PLC, AbbVie Inc, H. Lundbeck AS Class A, Supernus Pharmaceuticals Inc, Amneal Pharmaceuticals Inc Ordinary Shares - Class A, Cerevel Therapeutics Holdings Inc Ordinary Shares |
Other key industry trends
- In terms of revenue, Europe region accounted for 27.7% of the global parkinson’s disease treatment market in 2024.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 1,761.2 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Parkinson’s Disease Treatment Market Scope
Parkinson’s Disease Treatment Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Amneal Pharmaceuticals Inc Ordinary Shares - Class A | View profile | 7700 | 400 Crossing Boulevard, 3rd Floor, Bridgewater, NJ, United States, 08807 | https://www.amneal.com |
| Cerevel Therapeutics Holdings Inc Ordinary Shares | View profile | 355 | 222 Jacobs Street, Suite 200, Cambridge, MA, United States, 02141 | https://www.cerevel.com |
| Supernus Pharmaceuticals Inc | View profile | 652 | 9715 Key West Avenue, Rockville, MD, United States, 20850 | https://www.supernus.com |
| H. Lundbeck AS Class A | View profile | 5700 | Ottiliavej 9, Valby, Denmark, 2500 | https://www.lundbeck.com |
| GSK PLC | View profile | 70200 | 980 Great West Road, Brentford, Middlesex, United Kingdom, TW8 9GS | https://www.gsk.com |
| Merck & Co Inc | View profile | 72000 | 126 East Lincoln Avenue, Rahway, NJ, United States, 07065 | https://www.merck.com |
| AbbVie Inc | View profile | 50000 | 1 North Waukegan Road, North Chicago, IL, United States, 60064-6400 | http://www.abbvieinvestor.com |
| Teva Pharmaceutical Industries Ltd | View profile | 37851 | 124 Dvora HaNevi’a Street, Tel Aviv, Israel, 6944020 | https://www.tevapharm.com |
| Novartis AG ADR | View profile | 76057 | Lichtstrasse 35, Basel, Switzerland, 4056 | https://www.novartis.com |
Europe parkinson’s disease treatment market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to parkinson’s disease treatment market will help companies and investors design strategic landscapes.
Carbidopa-levodopa was the largest segment with a revenue share of 25.82% in 2024. Horizon Databook has segmented the Europe parkinson’s disease treatment market based on carbidopa-levodopa, dopamine agonist, mao-b inhibitors, comt inhibitors, anticholinergics covering the revenue growth of each sub-segment from 2018 to 2030.
Reasons to subscribe to Europe parkinson’s disease treatment market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Europe parkinson’s disease treatment market databook
-
Our clientele includes a mix of parkinson’s disease treatment market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Europe parkinson’s disease treatment market , including forecasts for subscribers. This continent databook contains high-level insights into Europe parkinson’s disease treatment market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Europe parkinsons disease treatment market size, by country, 2018-2030 (US$M)
Europe Parkinson’s Disease Treatment Market Outlook Share, 2024 & 2030 (US$M)
Related industry reports
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
